Phase 1/2a Study of ANPD001 in Parkinson Disease - Trial NCT06344026
Access comprehensive clinical trial information for NCT06344026 through Pure Global AI's free database. This Phase 1 trial is sponsored by Aspen Neuroscience and is currently Enrolling by invitation. The study focuses on Parkinson Disease. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Aspen Neuroscience
Timeline & Enrollment
Phase 1
Jan 23, 2024
Apr 30, 2030
Primary Outcome
Incidence and severity of treatment emergent adverse events (Safety and Tolerability)
Summary
This clinical trial is designed to test the safety and tolerability of injecting ANPD001
 cells that will mature into dopamine-producing cells into the brain of participants with
 Parkinson Disease. All participants will have ANPD001 cells manufactured from their own
 previously collected cells.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06344026
Non-Device Trial